Under the continuous transformation of the pharmaceutical industry, these three development trends remain unchanged

The pharmaceutical industry is an important industry related to the national economy and people's livelihood, and it is also a key area for the country to develop strategic emerging industries.
In order to better promote the high-quality development of the pharmaceutical industry, the country has issued a series of medical reform policies
.
It is worth noting that under the implementation of the policy, the domestic pharmaceutical industry has undergone more changes while developing in a healthier, standardized and high-quality manner
.
However, although the pharmaceutical market is beginning to become more volatile, from an overall perspective, the author believes that these three development trends will remain unchanged this year and for a long time to come
.
Under the continuous transformation of the pharmaceutical industry, these three development trends remain unchanged (Source: Pharmaceutical Network) Innovation will remain the general trend of the industry Under the pressure of a series of policies, the elimination process of the pharmaceutical market is continuing to accelerate
.
Especially as the policy of consistency evaluation becomes clear, the rules for drug bidding are gradually improved, and a large number of drugs are being withdrawn from the medical insurance catalogue at an accelerated pace, making room for drugs that have real therapeutic effects in clinical practice
.
Affected by the above situation, the industry predicts that as the elimination of the pharmaceutical industry continues to accelerate, 90% of generic drugs may withdraw from the market
.
In this context, in order to obtain more development opportunities, enterprises must either expand the scale, improve quality, control costs, and improve supply management; or increase investment in research and development of new drugs; or enter the market to accelerate the development of drug research and development and sales.

.
Among the many ways out, analysts believe that innovation will play a decisive role in the development of China's pharmaceutical industry, and this will further promote the development of China's innovative drug market
.
In the future, in order to seize new market development opportunities, pharmaceutical companies are expected to continue to increase investment in innovative drug research and development, and continue to promote the development of high-end generic drugs with core values
.
The wave of drug price cuts will continue.
Since 2018, six rounds of centralized procurement across the country have been carried out, and the centralized procurement of the entire pharmaceutical industry has gradually become normalized
.
Under the normalization of centralized procurement, the decline in drug prices has also become the general trend of the industry
.
Whether it is the selected drug or the unselected drug, the news of price reduction has been continuously spread in the industry
.
At present, the time has come to 2022, and the news of a large number of drug price cuts has been put on the agenda
.
For example, from January 1, Hubei, Hebei, Yunnan, Liaoning, Chongqing, Beijing and other places across the country have officially implemented the new drug list
.
It is understood that in the new version of the National Medical Insurance Drug List, 74 new drugs have been transferred to the list, and 11 drugs have been transferred out of the list
.
It is worth mentioning that in this negotiation, the average drop of 74 new drugs was 61.
71%
.
Among them, among the drugs in the newly promoted drug list, the price of the spinal muscular atrophy (SMA) rare disease treatment drug "Nosinagen Sodium Injection", which has attracted much attention, has been greatly reduced.
After being included in the medical insurance, the price of one injection has become 33,000 yuan
.
Therefore, according to the current industry centralized procurement trend, the industry believes that with the continuous expansion of centralized procurement in the future, it is expected that the prices of more drugs may be further reduced, benefiting more patients
.
Cooperation between pharmaceutical companies will become more frequent Influenced by changes in the pharmaceutical industry, pharmaceutical companies are accelerating the adjustment of their development strategies in recent years
.
On the whole, in these strategies, in addition to speeding up the layout of different pipelines; speeding up the "downsizing" and stripping off loss-making assets; a large number of pharmaceutical companies are still accelerating the formation of groups
.
It is reported that in the last year, cooperation and exchanges between domestic pharmaceutical companies and Chinese and foreign pharmaceutical companies have been very frequent
.
Incomplete statistics show that in October 2021, a total of 11 license in transactions have occurred in domestic pharmaceutical companies, and the disclosed transaction amount has exceeded 2.
2 billion US dollars
.
It is worth noting that China is currently actively promoting the development of innovative drugs, and has always insisted that innovative drugs need to adhere to the clinical value orientation
.
In this regard, the industry expects that with the development of innovative drugs in China and the continuous increase in R&D investment of enterprises, there may be more and more cooperation cases between domestic pharmaceutical companies and domestic and foreign pharmaceutical companies
.
With the continuous advancement of cooperation projects, the fruits of R&D cooperation between pharmaceutical companies will also be produced one after another
.